Nafamostat for sepsis-related clotting problems with hemofiltration
Treatments studied
Part of Blood & lymphatic, Infections, Kidney & urinary clinical trials.
This trial is testing a medicine called nafamostat mesylate for people with sepsis (a severe infection) that causes blood clotting problems and who are receiving hemofiltration (a type of blood filtering). The goal is to see if this medicine helps improve their recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a sepsis diagnosis (a severe infection) that is causing blood clotting problems.
- You must be undergoing a blood-filtering treatment called hemofiltration.
- You cannot be pregnant or breastfeeding.
- You must not have active bleeding or a high risk of bleeding (for example, recent head injury or a clotting disorder).
- Your fibrinogen level (a protein that helps blood clot) must not be too low (less than 1.5 g/L).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called nafamostat mesilate to help control blood clotting problems in people with severe infections (sepsis). It aims to reduce the risk of abnormal blood clots that can harm organs.
This trial is testing different doses of a blood thinner called nafamostat in patients who are in the ICU and need continuous kidney dialysis (CRRT). The goal is to find which dose works best to prevent clots in the dialysis machine without causing bleeding problems.
This trial tests a medicine called nafamostat mesilate to prevent blood clots in patients who need ECMO (a machine that helps your heart and lungs) after heart surgery. It may offer a safer way to thin the blood compared to standard treatments.
This study compares two blood-thinning drugs (nafamostat and heparin) that are given during dialysis for kidney failure caused by sepsis. The goal is to see which drug is safer and helps keep the dialysis filter working better.
This trial tests a new medicine called nafamostat to prevent blood clots during continuous dialysis (CRRT), for people who are at high risk of bleeding or can't take heparin.
This pilot study tests whether nafamostat is safe for people on hemodialysis who have a high risk of bleeding. It may help clinicians find safer ways to manage blood clotting medicines during dialysis.
Hear when a new Sepsis-induced Coagulopathy (SIC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.